Karen Akinsanya Biography and Net Worth

Insider of Schrodinger

Karen Akinsanya, Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D, joined Schrödinger in 2018. Karen leads our Discovery R&D group with responsibility for preclinical drug discovery and translational research. She has more than 25 years of experience in academia, pharmaceutical R&D, partnerships, and licensing. Karen joined Merck Research Labs in 2005 and held positions of increasing responsibility in clinical pharmacology as a development team leader working on first-in-human studies through late-stage label studies before joining Discovery Preclinical & Early Development as a therapeutic area lead and then a search and evaluation lead in business development. Karen received her Ph.D. from the Royal Postgraduate Medical School at Imperial College in London, in endocrine physiology. After post-doctoral training at Imperial and the Ludwig Institute for Cancer Research (UCL), Karen joined Ferring Pharmaceuticals in R&D working across sites in the UK and US. At Ferring, she led the discovery of a family of dipeptidyl peptidases related to DPPIV and pre-clinical characterization of FDA-approved FIRMAGON® for prostate cancer.

What is Karen Akinsanya's net worth?: The estimated net worth of Karen Akinsanya is at least $287.81 thousand as of April 14th, 2025. Dr. Akinsanya owns 15,625 shares of Schrodinger stock worth more than $287,813 as of December 5th. This net worth approximation does not reflect any other investments that Dr. Akinsanya may own. Additionally, Dr. Akinsanya receives an annual salary of $797,740.00 as Insider at Schrodinger. Learn More about Karen Akinsanya's net worth.
How old is Karen Akinsanya?: Dr. Akinsanya is currently 56 years old. There are 6 older executives and no younger executives at Schrodinger. The oldest executive at Schrodinger is Dr. Richard A. Friesner Ph.D., Co-Founder, Scientific Advisory Chairman and Director, who is 71 years old. Learn More on Karen Akinsanya's age.
What is Karen Akinsanya's salary?: As the Insider of Schrodinger, Inc., Dr. Akinsanya earns $797,740.00 per year. The highest earning executive at Schrodinger is Dr. Ramy Farid Ph.D., CEO, President & Director, who commands a salary of $1,060,000.00 per year. Learn More on Karen Akinsanya's salary.
How do I contact Karen Akinsanya?: The corporate mailing address for Dr. Akinsanya and other Schrodinger executives is 120 WEST 45TH STREET 17TH FLOOR, NEW YORK NY, 10036. Schrodinger can also be reached via phone at 212-295-5800 and via email at [email protected]. Learn More on Karen Akinsanya's contact information.
Has Karen Akinsanya been buying or selling shares of Schrodinger?: Karen Akinsanya has not been actively trading shares of Schrodinger within the last three months. Most recently, Karen Akinsanya sold 16,723 shares of the business's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $25.09, for a transaction totalling $419,580.07. Following the completion of the sale, the insider now directly owns 15,625 shares of the company's stock, valued at $392,031.25. Learn More on Karen Akinsanya's trading history.
Who are Schrodinger's active insiders?: Schrodinger's insider roster includes Robert Abel (Insider), Karen Akinsanya (Insider), Margaret Dugan (Insider), Jenny Herman (SVP), Rosana Kapeller-Libermann (Director), Joel Lebowitz (CFO), Kenneth Lorton (COO), Geoffrey Porges (CFO), David Shaw (Major Shareholder), Yvonne Tran (EVP), and Jorg Weiser (Director). Learn More on Schrodinger's active insiders.
Are insiders buying or selling shares of Schrodinger?: During the last twelve months, insiders at the sold shares 3 times. They sold a total of 23,609 shares worth more than $568,456.88. The most recent insider tranaction occured on October, 16th when insider Margaret Dugan sold 1,395 shares worth more than $29,392.65. Insiders at Schrodinger own 21.0% of the company. Learn More about insider trades at Schrodinger.
Information on this page was last updated on 10/16/2025.

Karen Akinsanya Insider Trading History at Schrodinger

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/14/2025	Sell	16,723	$25.09	$419,580.07	15,625
10/15/2021	Sell	1,393	$55.75	$77,659.75
9/15/2021	Sell	1,394	$61.13	$85,215.22	1,394
6/8/2021	Sell	10,242	$75.54	$773,680.68	6,479
12/18/2020	Sell	13,377	$80.00	$1,070,160.00	13,377
8/17/2020	Sell	3,344	$68.04	$227,525.76	3,344

Karen Akinsanya Buying and Selling Activity at Schrodinger

Schrodinger Company Overview

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Today's Range

Now: $18.42

$17.50

$18.42

50 Day Range

MA: $19.32

$16.33

$22.52

2 Week Range

Now: $18.42

$15.99

$28.47

Volume

720,261 shs

Average Volume

975,070 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Karen Akinsanya Biography and Net Worth

What is Karen Akinsanya's net worth?

How old is Karen Akinsanya?

What is Karen Akinsanya's salary?

How do I contact Karen Akinsanya?

Has Karen Akinsanya been buying or selling shares of Schrodinger?

Who are Schrodinger's active insiders?

Are insiders buying or selling shares of Schrodinger?